Interv Akut Kardiol. 2013;12(4):212-213
RELAX-AHF trial: new hope for acute heart failure treatment
- Kardiochirurgická klinika FN v Motole, Praha
Serelaxin is a novel recombinant form of human vasoactive peptide relaxin-2. The international randomized RELAX-AHF trial compared serelaxin
with placebo in patiens hospitalized for acute heart failure. Serelaxin improved primary endpoint – the visual analogue scale area under the
curve of patient-reported dyspnoea compared to placebo. There was no significant difference between placebo and serelaxin for the second
primary endpoint – Likert scale, measuring proportion of patients with dyspnoea improvement. Serelaxin improved some other symptoms of
heart decompensation. The secondary efficacy endpoints of cardiovascular mortality or rehospitalization for heart or renal failure at 60 days
were not significantly improved. Surprisingly, serelaxin therapy decreased cardiovascular and all-cause mortality at 180 days.
Keywords: serelaxin, acute heart failure, RELAX-AHF
Published: December 1, 2013 Show citation
References
- Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
Go to original source... 
Go to PubMed... - Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in acute heart failure study. Am Heart J 2012; 163: 149-155. Go to original source... Go to PubMed...
- Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39. Go to original source... Go to PubMed...